Abstract | PURPOSE: We examined the correlation between bone metabolic markers and bone scintigraphy in prostatic cancer. MATERIALS AND METHODS: RESULTS: All markers except for osteocalcin were significantly greater in patients with than without bone metastasis. Pyridinoline cross-linked carboxyterminal telopeptide, an osteoclastic marker, reflected the extent of bone metastasis more accurately than PSA and other bone markers. CONCLUSIONS:
Pyridinoline cross-linked carboxyterminal telopeptide might assist PSA and bone scintigraphy in monitoring metastatic bone activity of prostatic cancer.
|
Authors | H Maeda, M Koizumi, K Yoshimura, T Yamauchi, T Kawai, E Ogata |
Journal | The Journal of urology
(J Urol)
Vol. 157
Issue 2
Pg. 539-43
(Feb 1997)
ISSN: 0022-5347 [Print] United States |
PMID | 8996351
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Prostate-Specific Antigen
|
Topics |
- Adenocarcinoma
(blood, diagnostic imaging, secondary)
- Aged
- Aged, 80 and over
- Bone Neoplasms
(blood, diagnostic imaging, secondary)
- Humans
- Male
- Middle Aged
- Osteoblasts
(metabolism)
- Osteoclasts
(metabolism)
- Prostate-Specific Antigen
(blood)
- Prostatic Neoplasms
(blood, metabolism, pathology)
- Radionuclide Imaging
- Sensitivity and Specificity
|